Addex Therapeutics, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for the treatment of human health. Its lead programs include Dipraglurant (ADX48621) for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149 for epilepsy and an undisclosed central nervous system disorders; ADX71441 for the treatment of Charcot-Marie-Tooth type 1A neuropathy; and ADX71441 for the treatments of addiction. The Company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors.